O. C. P. Van Schayck (Maastricht, The Netherlands), T. van der Molen (Groningen, The Netherlands)
What factors identify COPD in general practice? A Delphi approach
M. Levy, R. J. Halbert, S. Isonaka, C. Justus (Aberdeen, United Kingdom; Santa Monica, United States Of America; Ingelheim, Germany)
|  |
Developing screening questionnaires for COPD
D. Price, D. Tinkelman, R. J. Halbert, S. Isonaka, D. Nonikov, J. Maroni (Aberdeen, United Kingdom; Denver, Santa Monica, New York, United States Of America; Ingelheim, Germany)
| |
Development of an instrument for predicting the exercise performance of patients with chronic obstructive pulmonary disease
E. J. Wagena, T. R. J. Schermer, R. Mostert, C. P. van Schayck, C. van Weel (Maastricht, Nijmegen, Horn, The Netherlands)
|  |
Association of depressive symptoms with gender in primary care COPD-patients: results from the COOPT study
N. H. Chavannes, M. J. H. Huibers, T. R. J. Schermer, A. Hendriks, C. Weel van, E. F. M. Wouters, O. P. Schayck van (Maastricht, Nijmegen, The Netherlands)
| |
Co-morbidities in patients with COPD in the UK
K. A. Lam, A. L. Hansell, S. Richardson, G. Visick, S. Joan (London, United Kingdom)
| |
Comparison of hospitalization risk for Medicaid patients with COPD by medication regimen
K. Rascati, R. Stanford, R. Borker (Austin, Raleigh, United States Of America)
| |
Cost-of-illness of COPD in Germany
D. Nowak, P. Oberender, K. Ueberla, A. Spannheimer, C. Schlegel, U. Reitberger, R. Welsch, S. Ruckdaeschel (Munich, Bayreuth, Ingelheim am Rhein, Karlsruhe, Germany)
| |
Salmeterol 50μg b.i.d. significantly increases though fev1 in COPD up to 12 months without loss of effect
R. A. Stockley, M. K. Williams, P. J. Whitehead (Edgbaston, Birmingham, Greenford, London, United Kingdom)
| |